Biopure Hemopure Advisory Committee For Hemorrhagic Shock Expected By September
This article was originally published in The Pink Sheet Daily
Executive Summary
The FDA committee would likely discuss circumstances under which the agency could lift a clinical hold that has been on the Hemopure trial since the IND was submitted in June 2005.
You may also be interested in...
Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study
Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.
Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study
Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.
FDA’s Emergency Research Regs Will Update “Community Informed Consent”
The agency is open to “possibilities” in terms of revising human subject protections.